Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03264391
Other study ID # 17100296
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2018
Est. completion date January 31, 2020

Study information

Verified date May 2020
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Behcet's disease is an important cause of retinal vasculitis and vision loss in Egypt. Fluorescein angiography is the standard method of diagnosis of retinal vasculitis. OCT angiography (OCT-A) is a recently developed method that can be used in the evaluation of retinal circulation. In this study, we will test the utility of OCT-A in diagnosis and follow up of retinal vascular changes in cases diagnosed with Behcet's disease that visit the outpatient uveitis clinic of Assiut University hospital, a major tertiary center in southern Egypt, over a one year duration. Also, correlation of OCT-A changes with visual acuity and hence prognosis will be described.


Description:

Aim of the research To describe macular retinal vascular changes in patient with retinal vasculitis secondary to Behcet's disease both qualitatively and quantitatively. Research design Type of the study: cross sectional analytical study Study Setting: Assuit University Hospital (Ophthalmology Department) Study subjects: 1. Inclusion criteria: • Patients diagnosed with Behcet's disease with or without active uveitis 2. Exclusion criteria: - Patients less than 18 years old - Hazy media precluding clear fundus view. - Patients with very poor fixation. 3. Sample Size Calculation: We will aim at recruiting all patients diagnosed with Behcet's disease in outpatient clinic who will meet the inclusion criteria within one year from the start of our project. Methods Subject recruitment and obtaining consent Study subjects (Behcet's patients) will be recruited from patients attending uveitis and retina clinic of the ophthalmology Department, Faculty of Medicine, Assiut University. Written informed consent form will be obtained from each patient. Baseline evaluation: 1. Full ocular examination including slit lamp and dilated fundus examinations. Also, measurement of the best corrected visual acuity (BCVA) using Snellen's chart will be done. 2. Thorough clinical history and review of other systems involvement as well as full drug history including use of topical and systemic medications. 3. Retinal vasculitis will be diagnosed by fundus examination. Additionally, fluorescein angiography may be done according to the discretion of the investigators to confirm the diagnosis. Optical coherence tomography angiography imaging OCT imaging will be performed after pupillary dilatation using Topcon DRI OCT Triton platform which utilizes invisible 1050 nm light and obtains images at a speed of 100,000 A scans/sec. First, B scans of the macula will be obtained and anatomical alterations of retinal architecture will be noted. Next, OCT angiography scans in a 4.5x 4.5 mm circle centered on the fovea will be then obtained. Analysis and interpretation of the enface images of the superficial and deep retinal capillary plexus as well as choriocapillaries will be performed. Areas of capillary dropout, abnormalities of retinal capillaries and vessels such as looping, dilated segments, microaneurysms as well as FAZ area will be documented. Research outcome measures: A. Primary (main): 1- Qualitative description of the retinal capillary plexus changes in the macular area B. Secondary: 1. Quantification of the extent of macular ischemia by measuring the area of foveal avascular zone (FAZ). 2. Correlation between extent of macular vascular changes and visual acuity Data management and analysis: Data collection data will be recorded in the form of excel spreadsheets Computer software SPSS and Prism graphpad Statistical tests chi square test and Pearson correlation coefficient


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date January 31, 2020
Est. primary completion date December 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - • Patients diagnosed with Behcet's disease Exclusion Criteria: - • Patients less than 18 years old - Hazy media precluding clear fundus view. - Patients with very poor fixation.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Faculty of medicine Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (3)

Bazvand F, Zarei M, Ebrahimiadib N, Karkhaneh R, Davoudi S, Soleimanzadeh M, Sharifian E, Roohipoor R, Modjtahedi BS. Ocular Manifestations, Conventional Fundus Fluorescein Angiographic Findings, and Relationship Between Angiographic Findings and Visual Acuity in Behçet's Disease. Semin Ophthalmol. 2017;32(6):764-771. doi: 10.1080/08820538.2016.1178310. Epub 2016 Aug 10. — View Citation

Fingler J, Readhead C, Schwartz DM, Fraser SE. Phase-contrast OCT imaging of transverse flows in the mouse retina and choroid. Invest Ophthalmol Vis Sci. 2008 Nov;49(11):5055-9. doi: 10.1167/iovs.07-1627. Epub 2008 Jun 19. — View Citation

Leitgeb RA, Schmetterer L, Hitzenberger CK, Fercher AF, Berisha F, Wojtkowski M, Bajraszewski T. Real-time measurement of in vitro flow by Fourier-domain color Doppler optical coherence tomography. Opt Lett. 2004 Jan 15;29(2):171-3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Qualitative description of the retinal capillary plexus changes in the macular area 1 year
Secondary Correlation between extent of macular vascular changes and visual acuity 1 year
See also
  Status Clinical Trial Phase
Completed NCT03274648 - Dietary Interventions and Butyrate Production in Behçet's Patients N/A
Terminated NCT01693653 - Tocilizumab for the Treatment of Behcet's Syndrome Phase 2
Completed NCT04961463 - Evaluation of the Psychoeducation Program Given to Behcet's Patients in the Context of the Roy Adaptation Model N/A
Completed NCT05142995 - Sleep Related Breathing Disorders, Anxiety, Depression and Quality of Life Assessment in Behcet's Disease
Recruiting NCT00931957 - Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease N/A
Completed NCT03514056 - Frequency of Fibromyalgia in Behcet Disease
Not yet recruiting NCT03771768 - Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease N/A
Terminated NCT03554161 - Tocilizumab for the Treatment of Refractory Behcet's Uveitis Phase 2
Recruiting NCT04738864 - Neuro-ultrasound Assessment in Behcet's Disease N/A
Completed NCT04386824 - Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
Completed NCT03962335 - Gut Microbiota and Behcet's Syndrome: a Dietary Intervention Trial (MAMBA Study) N/A
Completed NCT01532570 - Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions Phase 3
Not yet recruiting NCT04186559 - Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers Phase 2
Terminated NCT04218565 - Golimumab for the Treatment of Refractory Behcet's Uveitis Phase 2
Not yet recruiting NCT03747354 - Assessment of Disease Activity in Behcet by Complete Blood Count N/A
Recruiting NCT05200715 - AutoInflammatory Disease Alliance Registry (AIDA)
Completed NCT05098678 - Zinc Supplementation and Behçet's Syndrome N/A
Completed NCT00866359 - A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease Phase 2
Completed NCT00483184 - Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease Phase 2
Completed NCT05032248 - Uses of Tacrolimus in Behcet Disease N/A

External Links